Trials / Completed
CompletedNCT01430416
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
A Phase 1 Study of AEB071, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma. For dose expansion, the primary objective is to characterize the safety and tolerability of the MTD of AEB071 in patients with uveal melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AEB071 |
Timeline
- Start date
- 2011-12-20
- Primary completion
- 2019-05-22
- Completion
- 2019-05-22
- First posted
- 2011-09-08
- Last updated
- 2020-12-19
Locations
5 sites across 4 countries: United States, France, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT01430416. Inclusion in this directory is not an endorsement.